In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human ...

Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion ...

Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

Cancer cells can use lipids not just as fuel, but as a means to obscure inflammatory signals, enabling immune evasion.

PharmaJet and Scancell agreement builds on PharmaJet's strategy to be the best-in-class delivery system for novel DNA and RNA ...

In Type 1 diabetes (T1D), insulin-producing β-cells are killed by islet-infiltrating immune cells in a process called “insulitis”. T1D results in a critical requirement for exogenous insulin and ...

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept.

A local immunotherapy drug has been shown to significantly reduce melanoma while simultaneously recruiting immune cells to ...